The Federal Trade Commission Is Looking To Launch A Study About The Impact Of The Ballad Merger. Attorney Advisor For The FTC, Stephanie Wilkinson, Said The Study Has Not Been Authorized And It Would Take Several Years To Gather Meaningful Data. Ballad Health CEO Alan Levine Said A Study Would Be Premature. The Proposal Comes After Several Concerns Were Raised About Ballad’s COPA During A Recent FTC Workshop In Washington D.C.